Overview Financials News + Filings Key Docs Ownership
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results
|
Sol-Gel Technologies Ltd. (SLGL)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
09/28/2023 |
144
| Form 144 - Report of proposed sale of securities: |
09/27/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/10/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
08/10/2023 |
6-K
| Quarterly results |
07/27/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
07/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
07/20/2023 |
6-K/A
| Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] |
05/12/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
05/12/2023 |
6-K
| Quarterly results |
05/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
05/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/30/2023 |
6-K
| Quarterly results |
03/20/2023 |
SC 13D/A
| Arkin Moshe reports a 55.1% stake in Sol-Gel Technologies Ltd. |
03/10/2023 |
F-1
| Form F-1 - Registration statement for certain foreign private issuers: |
03/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
03/10/2023 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
03/01/2023 |
6-K
| Quarterly results |
02/14/2023 |
SC 13G/A
| Phoenix Holdings Ltd. reports a 10% stake in Sol-Gel Technologies Ltd. |
02/13/2023 |
6-K
| Quarterly results |
02/02/2023 |
6-K
| Quarterly results |
01/31/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"Form of SecuritiesPurchase Agreement",
"The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.",
"Sol-Gel Technologies Ltd.",
"Form of SecuritiesPurchase Agreement",
"NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Subscription, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows: 1. Subscription . The Investor agrees to buy, and the Company agrees to sell and issue to the Investor, 2,000,000 Ordinary Shares and Warrants to purchase 2,000,000 Ordinary Shares for an aggregate purchase price of $10.0 million on the same terms as the investors are acquiring the Securities in the Offering, including the form and terms of the Warrants to be issued to such Investors. The completion of the purchase and sale of the Ordinary Shares and the Warrants shall take place at the offices of Latham Watkins LLP, located at 1271 Avenue of th...",
"Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings" |
|
01/27/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
01/27/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
01/27/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"6-K",
"Domestic: 1-877-704-4453 International: 1-201-389-0920 Passcode: 13736097 The live conference call and replay can also be accessed by audio webcast here and also on the Investor Relations section of the Company’s website, located at https://ir.sol-gel.com/investor-relations . Slides for the accompanying corporate presentation can also be viewed at this link. About Gorlin Syndrome and SGT-610 SGT-610, a hedgehog signaling pathway blocker, has the potential to be the first ever treatment for Gorlin syndrome, if approved. Gorlin syndrome, an autosomal dominant genetic disorder affecting approximately 1 in 27,000-31,000 people in the U.S., is mostly caused by inheritance of one defective copy of the tumor suppressor gene PTCH1. Normally, the PTCH1 gene blocks the SMO gene, turning off the hedg..." |
|
01/26/2023 |
SC 13G
| Migdal Insurance & Financial Holdings Ltd. reports a 5.3% stake in Sol-Gel Technologies Ltd. |
11/21/2022 |
6-K
| Quarterly results |
10/03/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
08/04/2022 |
6-K
| Quarterly results |
06/23/2022 |
6-K
| Quarterly results |
06/08/2022 |
6-K
| Quarterly results |
05/23/2022 |
6-K/A
| Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] |
05/19/2022 |
6-K
| Quarterly results |
05/16/2022 |
6-K
| Quarterly results |
05/13/2022 |
6-K
| Quarterly results |
|
|
|